There has been significant research into the potential of  Immunoglobulin Y (IgY) as a solution to address some of today’s largest infectious and non-communicable human disease challenges ranging from pandemic preparedness to the realities of antibiotic resistance.


Our pipeline consists of the development of biologic drugs, therapeutics, and nutraceuticals that address some the largest areas of clinical needs.